Neuroblastoma (NB)Phase 1/2NCT06836505
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
A Phase 1/2 study testing CART therapy in people with Neuroblastoma (NB) and Desmoplastic Small Round Cell Tumor (DSRCT), run by Sun Yat-Sen University Cancer Center at 3 sites in China.
Trial summary
Title: Safety and efficacy of CAR-T cell therapy for relapsed/refractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial. The CART used in this study will be provided by Shanghai YaKe Biotechnology Ltd. Aims: 1. Read more about this study
- Who is it for?
- Ages 1 year to 50 years
- Conditions the study is for
- Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
- What is being tested?
- CART therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 3 sitesChina
- Study dates
- 12 Dec 2024to 12 Dec 2027
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 50 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients who are diagnosed as relapsed/refractory neuroblastoma or relapsed/refractory desmoplastic small round cell tumors;
- Age 1-50 years, any gender;
- Agree to participate in the trial and sign a written informed consent form;
- Expected survival of ≥12 weeks;
- Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients <16 years) (Appendix 1) must be at least 50;
- Good function of major organs:
Show all 14Show fewer
- Liver function: ALT ≤ 5 times the upper limit of normal for the corresponding age, and bilirubin ≤ 2.0 mg/dL, except for patients with Gilbert-Meulengracht syndrome. Patients with Gilbert-Meulengracht syndrome who have bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;
- Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m²;
- Pulmonary function: Oxygen saturation ≥ 95% in room air;
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;
- Patients using the following medications must meet the following conditions:
- Steroids: Steroid treatment doses must be stopped at least 2 weeks before CAR-T infusion. However, physiological replacement doses of steroids are allowed; Immunosuppressants: Any immunosuppressive drugs must be stopped at least 4 weeks before enrollment; Anti-proliferative treatments other than lymphodepleting chemotherapy within two weeks before infusion; CNS disease prophylaxis must be stopped 1 week prior to CAR-T infusion (e.g., intrathecal methotrexate injection);
- Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;
- If the subject cannot provide suitable T cells for CAR-T preparation, T cells from a healthy donor may be collected for preparation.
Who cannot join
- Patients with any of the following items will not be enrolled in this study:
- Patients with increased intracranial pressure or altered consciousness;
- Patients who have received radiation therapy within 2 weeks prior to infusion;
- Patients with active hepatitis B (defined as HBV DNA > 500 IU/mL) or hepatitis C (HCV RNA positive);
- HIV-positive patients or patients with a positive syphilis test;
- Patients with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood cultures within ≤72 hours before infusion);
Show all 17Show fewer
- Patients with unstable angina and/or myocardial infarction within 6 months prior to screening;
- Patients with a history of or concurrent malignancies, except for the following conditions:
- Basal cell carcinoma or squamous cell carcinoma that has been adequately treated (sufficient wound healing required before study enrollment);
- Carcinoma in situ of the cervix or breast that has been cured, with no signs of recurrence for at least 3 years before the study;
- Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;
- Pregnant or breastfeeding female patients;
- Patients with uncontrolled arrhythmias that have not been managed medically;
- Patients who need oral anticoagulation therapy within 1 week before CAR-T cell infusion;
- Patients with active neuroautoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis);
- Other conditions deemed inappropriate for participation in the clinical study by the investigator.
- Patients enrolled in the clinical study must meet the inclusion criteria and not meet the exclusion criteria.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Suying Lu, PhD contact
China3 sites, 3 recruiting
- Recruiting
Dongguan Taixin Hospital
Dongguan, Guang, 523125
Cunfu Li, 0769-33335678, chunfugzcn@vip.126.com
- Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060
Yizhuo Zhang, 020-87342460, zhangyzh@sysucc.org.cn
- Recruiting
Shanghai YaKe Biotechnology Ltd.
Shanghai, Shanghai Municipality, 200438
ALEX HONGSHENG CHANG, 021-55088295, changah@yakebiotech.com
About this study
Title: Safety and efficacy of CAR-T cell therapy for relapsed/refractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial.
The CART used in this study will be provided by Shanghai YaKe Biotechnology Ltd.
Read more
Aims:
- To evaluate the safety and efficacy of GD2/B7H3 CAR-T therapy for relapsed/refractory neuroblastoma, and observe its pharmacokinetic/pharmacodynamic characteristics and the survival of CAR-T cells in relapsed/refractory neuroblastoma patients.
- To evaluate the safety and efficacy of GD2/B7H3 CAR-T therapy for relapsed/refractory desmoplastic small round cell tumor, and observe its pharmacokinetic/pharmacodynamic characteristics and the survival of CAR-T cells in desmoplastic small round cell tumor patients.
Patients: Relapsed/refractory neuroblastoma; Relapsed/refractory desmoplastic small round cell tumor.
CAR-T therapy: Lymphodepletion treatment will be performed within 14 days prior to CAR-T cell infusion: intravenous chemotherapy based on fludarabine 25mg/m² and cyclophosphamide 500mg/m² for 1 to 3 days. CAR-T cells will then be infused intravenously, with a dosage of 1.00 to 10.00 × 10⁶/kg of CAR-positive T cells.
Research period: CAR-T cell infusion will be followed up for one year, or until adverse events resolve, progression occurs, or the patient transitions to other treatments.
Outcome measures:
Incidence of adverse events related to CAR-T therapy, as well as their intensity and duration; Pharmacokinetic/pharmacodynamic characteristics of CAR-T in patients and the survival of CAR-T cells.
Overall response rate (ORR) after CAR-T cell infusion, including complete response (CR) and partial response (PR); Overall survival (OS), progression-free survival (PFS), event-free survival (EFS), time to progression (TTP), and duration of response (DOR) after CAR-T cell infusion;
Read the detailed description
Main objective:
To evaluate the safety, pharmacokinetic/pharmacodynamic characteristics and the survival of CAR-T cells in relapsed/refractory neuroblastoma and desmoplastic small round cell tumor patients.
Secondary objectives:
To evaluate the efficacy of CAR-T cells in relapsed/refractory neuroblastoma and desmoplastic small round cell tumor patients.
Patients: Relapsed/refractory neuroblastoma; Relapsed/refractory desmoplastic small round cell tumor.
CAR-T therapy: Lymphodepletion treatment will be performed within 14 days prior to CAR-T cell infusion: intravenous chemotherapy based on fludarabine 25mg/m² and cyclophosphamide 500mg/m² for 1 to 3 days. CAR-T cells will then be infused intravenously, with a dosage of 1.00 to 10.00 × 10⁶/kg of CAR-positive T cells.
Research period: CAR-T cell infusion will be followed up for one year, or until adverse events resolve, progression occurs, or the patient transitions to other treatments.
Outcome measures:
Incidence of adverse events related to CAR-T therapy, as well as their intensity and duration; Pharmacokinetic/pharmacodynamic characteristics of CAR-T in patients and the survival of CAR-T cells.
Overall response rate (ORR) after CAR-T cell infusion, including complete response (CR) and partial response (PR); Overall survival (OS), progression-free survival (PFS), event-free survival (EFS), time to progression (TTP), and duration of response (DOR) after CAR-T cell infusion;
- Being tested
- CART therapy
- Keywords
- CART, Neuroblastoma, Desmoplastic Small Round Cell Tumor
- Medical subject headings
- Neuroblastoma, Desmoplastic Small Round Cell Tumor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CART therapyBiological
GD2/B7H3 CAR T-cell therapy
| Study group | Role | What they receive |
|---|---|---|
| Safety and efficacy of CAR-T cell therapy for relapsed/refractory NB and DSRCT | Experimental | Not described Receives: Biological: CART therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the safety of CAR-T cells in relapsed/refractory neuroblastoma and desmoplastic small round cell tumor patients.
- To evaluate the safety of the infusion of CAR T cells at different escalating/deescalating doses and establish the dose limiting toxicity (DLT) of the cellular product. Toxicity will be evaluated according to the CTC AE scale, version 4.0. DLT will be defined as any of the following that is not pre-existing, due to infection or to underlying malignancy and that may be considered possibly, probably or definitely related to the study cellular products. (1) Non-hematologic DLT is any grade 3 or 4 non-hematologic toxicity; (2) Hematologic DLT is defined as any grade 4 hematologic toxicity related to infusion ; (3) Grade 4 reactions related to infusion; (4) Death related to CAR T cells infusions. The incidence of grade 3-5 toxicities, with a main attention to severe Cytokine Release Syndrome (CRS), will be evaluated.
- To determine the optimal dose of CAR transduced T cells resulting in the control of the disease without inducing unacceptable levels of toxicity (MTD) .
Measured: From enrollment to the end of treatment at 1 year
Secondary outcomes (1)
To evaluate the efficacy of CAR-T cells in relapsed/refractory neuroblastoma and desmoplastic small round cell tumor patients.
To assess the antitumor effect of iC9-GD2-CAR T cells at 6 weeks, 3 and 6 months post-infusion. The Best Overall Response Rate (BOR) and the proportion of neuroblastoma patients achieving complete remission (CR) will be assessed according to INRC. The Best Overall Response Rate (BOR) and the proportion of desmoplastic small round cell tumor patients achieving complete remission (CR) will be assessed according to RECIST 1.1.
Measured: From enrollment to the end of treatment at 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2025
- Study start12 Dec 2024
- Primary completion12 Dec 2027 (estimated)
- Study completion12 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuroblastoma (NB)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-Sen University Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Yake Biotechnology Ltd., Dongguan Taixin Hospital
- Responsible party
- Principal investigator, Yizhuo Zhang, Sun Yat-sen University
- Investigators
- Yizhuo Zhang, Principal investigator, Sun Yat-Sen University Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06836505
- Sponsor's protocol ID
- TXEC-2024-025
- Status last verified
- Dec 2024
- First submitted
- 25 Jan 2025
- Last updated
- 26 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No